Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer.

Zendejas B, Moriarty JP, O'Byrne J, Degnim AC, Farley DR, Boughey JC.

J Clin Oncol. 2011 Aug 1;29(22):2993-3000. doi: 10.1200/JCO.2011.35.6956. Epub 2011 Jun 20.

2.

Cost-effectiveness of contralateral prophylactic mastectomy for prevention of contralateral breast cancer.

Roberts A, Habibi M, Frick KD.

Ann Surg Oncol. 2014 Jul;21(7):2209-17. doi: 10.1245/s10434-014-3588-7. Epub 2014 Mar 17.

PMID:
24633665
3.

Outcomes of contralateral prophylactic mastectomy in relation to familial history: a decision analysis (BRCR-D-16-00033).

Davies KR, Brewster AM, Bedrosian I, Parker PA, Crosby MA, Peterson SK, Shen Y, Volk RJ, Cantor SB.

Breast Cancer Res. 2016 Sep 20;18(1):93. doi: 10.1186/s13058-016-0752-y.

4.

Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients.

Bedrosian I, Hu CY, Chang GJ.

J Natl Cancer Inst. 2010 Mar 17;102(6):401-9. doi: 10.1093/jnci/djq018. Epub 2010 Feb 25.

5.

Survival outcomes after contralateral prophylactic mastectomy: a decision analysis.

Portschy PR, Kuntz KM, Tuttle TM.

J Natl Cancer Inst. 2014 Jul 16;106(8). pii: dju160. doi: 10.1093/jnci/dju160. Print 2014 Aug.

PMID:
25031308
6.

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.

Grann VR, Panageas KS, Whang W, Antman KH, Neugut AI.

J Clin Oncol. 1998 Mar;16(3):979-85.

PMID:
9508180
7.

The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation.

Robertson C, Arcot Ragupathy SK, Boachie C, Dixon JM, Fraser C, Hernández R, Heys S, Jack W, Kerr GR, Lawrence G, MacLennan G, Maxwell A, McGregor J, Mowatt G, Pinder S, Ternent L, Thomas RE, Vale L, Wilson R, Zhu S, Gilbert FJ.

Health Technol Assess. 2011 Sep;15(34):v-vi, 1-322. doi: 10.3310/hta15340. Review.

8.

Prophylactic mastectomy for the prevention of breast cancer.

Lostumbo L, Carbine N, Wallace J, Ezzo J.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. Review. Update in: Cochrane Database Syst Rev. 2010;(11):CD002748.

PMID:
15495033
9.

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.

Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.

J Natl Cancer Inst. 2014 Nov 30;107(1):380. doi: 10.1093/jnci/dju380. Print 2015 Jan.

10.

Contralateral prophylactic mastectomy in an Asian population: a single institution review.

Sim Y, Tan VK, Ho GH, Wong CY, Madhukumar P, Tan BK, Yong WS, Ng YY, Ong KW.

Breast. 2014 Feb;23(1):56-62. doi: 10.1016/j.breast.2013.10.008. Epub 2013 Nov 23.

PMID:
24275318
11.

Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.

Ishiguro H, Kondo M, Hoshi SL, Takada M, Nakamura S, Teramukai S, Yanagihara K, Toi M.

Clin Ther. 2010 Feb;32(2):311-26. doi: 10.1016/j.clinthera.2010.01.029.

PMID:
20206789
12.

Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.

Pesce C, Liederbach E, Wang C, Lapin B, Winchester DJ, Yao K.

Ann Surg Oncol. 2014 Oct;21(10):3231-9. doi: 10.1245/s10434-014-3956-3. Epub 2014 Aug 1.

PMID:
25081341
14.

Contralateral prophylactic mastectomy in breast cancer patients who test negative for BRCA mutations.

Howard-McNatt M, Schroll RW, Hurt GJ, Levine EA.

Am J Surg. 2011 Sep;202(3):298-302. doi: 10.1016/j.amjsurg.2011.04.001.

PMID:
21871984
15.

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.

Am J Manag Care. 2006 Jul;12(7):374-86.

16.

Is prophylactic fixation a cost-effective method to prevent a future contralateral fragility hip fracture?

Faucett SC, Genuario JW, Tosteson AN, Koval KJ.

J Orthop Trauma. 2010 Feb;24(2):65-74. doi: 10.1097/BOT.0b013e3181b01dce.

PMID:
20101129
17.

Economic evaluation of genomic test-directed chemotherapy for early-stage lymph node-positive breast cancer.

Hall PS, McCabe C, Stein RC, Cameron D.

J Natl Cancer Inst. 2012 Jan 4;104(1):56-66. doi: 10.1093/jnci/djr484. Epub 2011 Dec 2.

PMID:
22138097
18.

Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer.

Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ.

Am J Surg. 2000 Dec;180(6):439-45.

PMID:
11182394
19.

Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.

King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M, Morrow M.

J Clin Oncol. 2011 Jun 1;29(16):2158-64. doi: 10.1200/JCO.2010.29.4041. Epub 2011 Apr 4.

PMID:
21464413
20.

Issues of regret in women with contralateral prophylactic mastectomies.

Montgomery LL, Tran KN, Heelan MC, Van Zee KJ, Massie MJ, Payne DK, Borgen PI.

Ann Surg Oncol. 1999 Sep;6(6):546-52.

PMID:
10493622

Supplemental Content

Support Center